Table 2.

Associations between sodium-glucose cotransporter 2 (SGLT2) inhibitor use and mortality among 24,915 non-small cell lung cancer patients.

	Number of deaths /number of patients	HR (95% CI)a
SGLT2 inhibitor use
No	17,921/24,384	Reference
Yes	260/531	0.68 (0.60–0.77)
Duration of use
<12 months	179/312	0.76 (0.66–0.89)
≥12 months	81/219	0.54 (0.44–0.68)
P for trend		0.0001
Canagliflozin use
No	17,993/24,591	Reference
Yes	188/324	0.88 (0.76–1.01)
Duration of use
<12 months	128/197	0.96 (0.80–1.14)
≥12 months	60/127	0.74 (0.58–0.96)
P for trends		0.03
Combination of metformin and SGLT2 inhibitors use
Neither	12,519/16,688	Reference
Metformin only	5402/7696	0.93 (0.90–0.96)
SGLT2 only	70/129	0.71 (0.56–0.89)
Both	190/402	0.62 (0.54–0.72)

^aModels were adjusted for age at diagnosis, sex, race/ethnicity, marital status, chronic conditions (chronic kidney disease, hypertension, cardiovascular disease), cancer stage, cancer histological types (squamous cell carcinoma, adenocarcinoma, other types), cancer treatment (cancer-directed surgery, chemotherapy, radiation, immunotherapy and EGFR antagonist) and diabetes duration. All models were also adjusted for metformin use except for the analysis of combination of metformin and SGLT2 inhibitors use.